AXL overexpression is a common resistance mechanism to anti-cancer therapies, including the p110 isoform specific inhibitor of the phosphoinositide 3-kinase (PI3K), BYL719, in esophagus and head and neck squamous cell carcinoma (ESCC, HNSCC respectively). However, the mechanisms underlying AXL overexpression in resistance to BYL719 remained elusive. Here we demonstrated that the AP-1 transcription factors, c-JUN and c-FOS, regulates AXL overexpression in HNSCC and ESCC. AXL and c-JUN expression is correlated in HNSCC patients, and in HNSCC and ESCC cell lines. Silencing of c-JUN and c-FOS expression in tumor cells reduced AXL expression, and enhanced sensitivity of human papilloma virus positive (HPV Pos ) and negative (HPV Neg ) tumor cells to BYL719 in vitro. Blocking of the c-JUN N-terminal kinase (JNK), using SP600125, in combination with BYL719 resulted in down-regulation of AXL expression, and potently inhibited mTOR pathway. Synergistic anti-proliferative effect was detected between BYL719 and SP600125 in 15 tumor cell lines in vitro. In-vivo, this drug combination induced tumor growth arrest in cell line and patients-derived xenograft models, and in syngeneic head and neck cancer models. Collectively, our data suggests that JNK inhibition in combination with anti-PI3K therapy is a new therapeutic strategy that may be tested in HPV Pos and HPV Neg HNSCC and ESCC patients.
Introduction
The unsatisfactory outcomes of current therapies for squamous cell carcinoma of head and neck, and esophagus (HNSCC and ESCC, respectively) patients are underscored by the high mortality and morbidity rates of the diseases (1, 2) . Taken together with the high incidence rates per year in many countries (3, 4) , the development of new therapeutic approaches is urgently needed.
The etiology of HNSCC and ESCC is linked with alcohol consumption and smoking, and in recent years also with the emergence of the human papilloma virus (HPV) infection (Reviewed in (5) ). Despite the significant differences in the molecular landscape of HPV-positive (HPV Pos ) and HPV-negative (HPV Neg ) HNSCC and ESCC (6) (7) (8) , genomic alterations in the PIK3CA gene are frequent, regardless of HPV status (6) (7) (8) . PIK3CA encodes for the p110 subunit of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K). Activating point mutations or amplifications of the PIK3CA gene results in the hyper-activation of the PI3K/AKT/mTOR signaling pathway (Review in (9) ). This pathway plays a key role in regulating cell proliferation and survival; hence in PIK3CA-mutated HNSCC and ESCC, PI3K enhances tumor progression. Due to the importance of this pathway in HNSCC and ESCC, blockers of the PI3K, AKT and mTOR are under clinical development (Review in (10) (11) (12) ). Recently, Dejan et al reported that 14 out of 17 PIK3CA-mutated HNSCC patients benefited from a single agent of the isoform specific p110 inhibitor BYL719 (Alpelicib) (13) . However, all patients eventually developed resistance to BYL719 (13) . We recently showed that the emergence of resistance to BYL719 in HNSCC and ESCC involves the overexpression of the receptor tyrosine kinase (RTK) AXL. AXL dimerizes with epithelial growth factor receptor (EGFR) to signal through the phospholipase Cγ (PLCγ)-protein kinase C (PKC) pathway, leading to the reactivation of mTOR in an AKT independent manner (14) . We further showed that AXL overexpression is associated with resistance to BYL719 in patients with HNSCC, and inhibition of AXL using R428 can reverse the resistance to BYL719 (14) . AXL seems to be a central RTK that play a key role in resistance to anti-cancer therapies, as elevated expression of AXL was observed in tumors that became resistance to various therapies (15) (16) (17) (18) (19) . These evidence emphasize the need to block AXL activity in order to improve drugs efficacies in patients. In fact, blockers of AXL using small molecules or antibodies are under clinical development (ClinicaTtrials.org). However, to the best of our knowledge, targeting the expression of AXL as an alternative therapeutic strategy was not explored yet.
Axl gene transcription was shown to be regulated by several transcription factors (TFs) such as SP1\3 (20) and MZF1 (21) in colon and cervix cancers, and AP-1 complex in melanoma, leukemia and bladder cancers (22) (23) (24) . However, the TFs that regulate AXL overexpression in ESCC and HNSCC following resistance to PI3K therapy remain uncharacterized. Here we identified the transcriptional machinery that regulates AXL expression in these cancers, and tested new drug combination to limits AXL expression, and to improve the efficacy of BYL719 in vitro and in vivo.
Results

AXL expression determines sensitivity to BYL719 in HPV Pos and HPV Neg cancer cell lines.
We recently showed that AXL overexpression drives acquisition of resistance to BYL719 in cell lines and in HNSCC patients (14) . To test if the basal expression of AXL also determines the primary sensitivity to BYL719, we knocked down the expression of AXL in HPV Pos and HPV Neg HNSCC and ESCC cell lines, and measured the half maximal inhibitory concentration (IC:50) of BYL719 in vitro. For HPV Neg cells we used SNU1076 (HNSCC), and our previously established isogenic tumor cell line model, BYL719-sensitive KYSE180 (KYSE180 Sen ) and their counterpart BYL719-resistant model (KYSE180 Res ) (ESCC) that showed AXL overexpression (14) . For HPV Pos cell line UMSCC47 was used. Knockdown of AXL significantly reduced BYL719 IC:50 values in all tumor cells ( Figure 1 .A). Western-blot (WB) analysis of the KYSE180 Sen tumor cells following treatment with BYL719 showed that AXL expression impact the potency of BYL719 to block mTOR pathway. Specifically, further inhibition of phosphorylation levels of ribosomal protein S6 (pS6), was detected in tumor cells that AXL expression was knocked down (Figure 1 .B). These results align with our previous report showing that AXL bypass AKT to active mTOR pathway (14) .
Next, we confirmed the effect of AXL knockdown on the efficacy of BYL719 in vivo, using a cell line-derived xenograft model (CDX) of KYSE180 Sen -shCT and shAXL1 tumor cells. In agreement with the in vitro studies, BYL719 treatment delayed the growth of the shAXL tumors more efficiently compared with shCT tumors (Figure 1 .C). This was associated with a reduction in mTOR pathway activation measured by pS6 immunohistochemistry (IHC) staining, and a reduction in tumor cell proliferation, measured by Ki67 IHC (Figure 1 .D-E). Similar results were obtained in the HPV Pos UMSCC47-derived CDX model ( Supplementary Figure 1 .A-D).
Resistance to BYL719 is associated with c-JUN transcription factor upregulation
As the expression level of AXL determined the response of HNSCC and ESCC cells to BYL719, we aimed to identify the molecular machinery that regulates AXL overexpression, using isogenic BYL719-sensitive, and resistant models (KYSE180 Sen vs. KYSE180 Res , CAL33 Sen vs. CAL33 Res ) (14) . A gene enrichment set analysis of the RNAseq obtained in these cells identified over 100 conserved motifs (padj>0.1X10-5) of 41 TF that were significantly activated ( Supplementary Table   1 ). TCF3, SP-1, AP-1 and MYC were among the most significant TF signatures that were upregulated in both resistant cells. Three of the 41 TF were predicted to have binding sites on AXL promotor (QIAGEN-transcription factor analysis); AP-1, MYC, and MYC Associated Zinc Finger (Figure 2 .B-C). SP1 transcription factor (previously reported to regulate AXL expression (20, 25) ) was upregulated in only in KYSE180 Res cells but not in CAL33 Res cells. Moreover, we observed an inverse correlation between AXL and microphthalmia-associated transcription factor (MITF) as previously reported for resistance to multiple targeted drugs in melanoma (23, 26, 27) (Figure 2 Table 1 ). Validation of expression of AXL and c-JUN in an independent cohort of 10 freshly isolated HNSCC tumor specimens from Soroka Medical Center were analyzed by WB and by IHC showed a similar trend (R=0.5254, p=0.011, Figure 3 .B).
In addition, a positive correlation between AXL and c-JUN expression was detected in 5 HNSCC patient derived xenografts (PDXs) (R=0.969, p=0.0063, Supplementary Figure 3 .D), and in a panel of 17 HNSCC and ESCC cell lines (R=0.308, p=0.0085, Figure 3 .C). The BYL719 IC:50 values of the tested cell lines were also correlated to AXL and c-JUN expression, as most cell lines with high IC:50 values showed high expression levels of AXL and c-JUN (shown by the size of the round symbols in the graph representing each cell line in Figure 3 .C, and in Supplementary Figure 3 .E).
Collectively, the strong positive correlation found between AXL and c-JUN expression in HNSCC and ESCC clinical sample and in cell lines support our finding that AXL expression is transcriptionally regulated by AP-1 complex, which potentially can be a therapeutic target to enhance efficacy of BYL719.
Knockdown of AP-1 members and inhibition of the c-JUN N-terminal kinase enhance BYL719 efficacy in vitro.
As AXL expression is regulated by the AP-1 transcription complex, we hypothesized that c- Figure 4 .B). Notably, KYSE180 Res cells were sensitized to BYL719 using SP600125 to similar IC:50 values as KYSE180 Sen cells, suggesting that the combined treatment may inhibit the emergence of resistance. A cell proliferation assay monitoring growth rates of the cells showed that the combined treatment of BYL719 and SP600125 had a superior anti-proliferative effect, and potentially cell death in HPV Pos SCC60A cell line ( Supplementary Figure 4 .C). WB analysis showed that while BYL719 upregulated AXL expression, its combination with SP600125 (10M) decreased AXL protein levels (Figure 4 .C). The level pS6, was further inhibited by the combination of BYL719 and SP600125 in KYSE180 Res and SNU1076 cells. A qPCR analysis showed that AXL mRNA levels were initially increased following BYL719 treatments in KYSE180 Sen 
Superior efficacy of a combined treatment with BYL719 and SP600125 in vivo
To explore the efficacy of BYL719 and SP600125 combination in vivo, CDX models of KYSE180 Sen (HPV Neg ) and UTSCC47 (HPV Pos ) cells were created, and tumor growth was measured.
Daily treatments of mice with monotherapy of BYL719 (25 mg/kg) delayed tumor growth compared to vehicle treatment. However, a significant tumor growth arrest (in HPV Neg KYSE180 Sen CDXs) and tumor shrinkage (in HPV Pos UTSCC47 CDXs) were observed in mice treated with the combination of BYL719 and SP600125 ( Figure 5 . A-B, Supplementary Figure 5 .A-B). We did not detect any toxicity, as mice weight remained stable (Supplementary Figure 5 .A-B). IHC staining of the proliferation marker, Ki67, showed a decreased tumor cell proliferation in tumors treated with BYL719 and SP600125 monotherapy. However, a greater inhibition of cells proliferation was detected in tumors treatment with the combination.
To further validate our observation in pre-clinical models, the efficacy of drug combination was tested in two PDX models (SE1 and SE3). Treatments of mice with the combination of BYL719 and SP600125 showed a superior anti-tumor effect as shown by tumor volumes and tumor weights 
Enhanced anti-tumor efficacy of BYL719 and SP600125 prevents tumor progression and enhances survival in syngeneic head and neck cancers
To further verify our findings in syngeneic HNSCC tumors, we developed HPV Neg tumors, and explored the efficacy of BLY719 and SP600125 in C57BL/6 mice. Lips and tongue squamous cell carcinoma tumors developed following exposure of C57BL6/c mice to the carcinogen 4NQO in the drinking water as previously reported (30) (Supplementary Figure 6 .A). IHC analysis of the 4NQO-induced-tongue cancer showed that in malignant lesion (Ki67 and KRT14 positive staining), the AKT pathway is active, and that AXL and c-JUN are expressed in cancer cells ( Figure 6 .A).
Following generation of two cell lines derived from the lips and tongue tumors, we studied the efficacy of BYL719 and SP600125 in vitro and in vivo. In vitro, tumor cell proliferation studies showed that BYL719 and SP600125 combination had a superior anti-proliferative activity, which was associated with a reduction of pS6 levels as shown by WB analysis (Figure 6 .B-C). In vivo, the efficacy of the drugs combination had a significant anti-tumor effect in two syngeneic cancer models. Lips tumors displayed a stable disease in mice treated with BYL719 and SP600125 combination, compared with tumor progression mice treated with either BYL719 or SP600125 ( Figure 6 .E). In an orthotropic tongue cancer model, BYL719 and SP600125 combination significantly improved the survival of the mice. The median survival for vehicle and SP600125 treated mice was 16 and 17 days, respectively, and for BYL719 treated mice, 23.5 days. However, the median survival of mice in the combination group was 52 days. MRI imaging supported the finding, as drugs combination delayed tumor progression ( Figure 6 .D).
Discussion
In this work, we demonstrated that AXL levels determine the sensitivity of HPV Neg and HPV Pos HNSCC and ESCC cells to BYL719. We identified the AP-1 transcriptional complex as a regulator of AXL expression in these diseases, and demonstrated that JNK inhibition enhances the anti-tumor efficacy of BYL719 in vitro and in vivo (Scheme 1).
The rationale for targeting the PI3K pathway in several malignancies including in head and neck cancer, using isoform specific inhibitors was well demonstrated (13, (31) (32) (33) (34) (35) (36) (37) . The first clinical trial testing the p110 isoform specific inhibitor BYL719, showed encouraging results in PIK3CA mut head and neck cancer (13) . The major obstacle in implementing BYL719 in HNSCC and ESCC is the primary and the acquired-resistance that is driven by the overexpression of AXL (14) . This overexpression of AXL in response to therapy is not exceptional to either these malignant diseases or to PI3K therapies, as other cancer types developed resistance to radiotherapy, chemotherapies and EGFR inhibitors via AXL pathway activation (15) (16) (17) (18) (19) (38) (39) (40) . Hence, targeting AXL receptor and its pathway using the small molecule inhibitors (such as BGB324, ONO-747, TP-0903, MGCD516 and BPI-9016M) or specific antibodies (CAB-AXL-ADC) are under clinical evaluation in 14 clinical trials as monotherapy or in combination with other therapies in different settings (clinicaltrials.gov).
The clinical outcomes of these studies are not yet available, but pre-clinical models indicate that the efficacy of a single agent of AXL therapies can be limited by expression of other receptors like MERTK (41) , while in combination, the potency is enlarged (15, 40, (42) (43) (44) (45) (46) (47) .
Here we took an alternative approach to reduce availability of AXL by limiting its transcription.
Initially, we demonstrated that AXL levels determine the efficacy of BYL719 in HNSCC and ESCC cells in vitro and in vivo, which supported the rationale to reduce AXL expression in tumor cells in order to enhance BYL719 efficacy. This observation is applicative to HPV Pos and HPV Neg HNSCC and ESCC, which may overcome the primary resistance to BYL719 reported recently in HPV Pos cells (48) . We gained an additional confidence for our approach to reduce AXL expression level as a therapeutic opportunity, as Wheeler's group showed that reduction of AXL expression enhances the efficacy of cetuximab in HPV Pos and HPV Neg HNSCC tumors (15, 49) .
AXL overexpression in response to therapeutic stress can evolve through several mechanisms such as transcriptional regulation (50, 51) (52) (15, 23, 24) , post-translational regulation (53, 54) , and expression of miRNA (55) (Reviewed in (56) Lastly, blocking AP-1 complex can also reduce the expression of the immuno-suppressor modulator of PD-L1 (65), and enhance tumor elimination. This possibility is also supported by the notion that AXL and PD-L1 expression are correlated in different cancers (66, 67) , and in TCGA data set of head and neck cancer (data not shown). However, further analysis need to be conducted to confirm this hypothesis in our model.
In summary, we present solid evidence that upregulation of AXL in PI3K-resistance cells is regulated by the AP-1 transcription factors. Knockdown of AXL or AP-1 resulted in enhance antitumor efficacy of BYL719. Targeting of JNK using SP600125 together with BYL719 had a potent anti-tumor activity against HPV Pos and HPV Neg cells. Such results provide a strong rationale to investigate these drug combinations in HNSCC and ESCC patients.
Material and Methods
Tumor Cell Lines
All HPV Neg cell lines were purchased from commercial vendors. Cell lines sources and specific media is presented in Supplementary materials and methods. KYSE180 Res and CAL33 Res cell lines that were BYL719 resistant were developed previously (14) , and SNU1076 resistant cell lines was developed using the same approach as previously described (14) . 
Immunohistochemistry (IHC) and Immunofluorescence (IF).
Tissues were fixed in a 4% PFA solution for a maximum of 24 hours at room temperature, dehydrated and embedded in paraffin. The tissue sections were de-paraffinzed with xylene. 3%. IHC and IF slides were digitalized using the Pannoramic Scanner (3DHISTECH, Budapest, Hungary) and analyzed using QuantCenter (3DHISTECH, Budapest, Hungary) using a single threshold parameter for all images of a specific staining in each experiment.
Tissue Microarray
Tissue microarray slides containing 17 HNSCC and 15 benign tumors were purchased from US Biomax (HNT961). The information of these samples and the level of AXL and c-JUN was summarized in Supplementary Table 2 .
IC:50 and synergy assay
Cells were seeded in 96-well plates (3000 cells per well), treated with increasing concentration of indicated drugs (0-10M), and allowed to proliferate for 4 days. Cells were then fixed using For the creation of shRNAs cell lines, we created lentiviruses by transfecting HEK293 cells with the viral plasmids psPAX2, pMD2.G, and PLKO with shRNAsa control scrambled sequence (shCT), or 2 different sequences for the silencing of AXL expression (shAXL1 and shAXL2, MSKCC RNAi core facility identifiers TRCN0000001037 and TRCN0000194771, respectively) using PolyJet transfection reagent (SignaGen, Cat. SL100688). Viruses were collected following 48-72hr and used for cell infection. Cells were seeded in a 6 well plate (150000 cells per well) and infected with the lentiviruses in the presence of polybrene (Sigma Aldrich Cat. 5G-H9268). Cells were selected using puromycin (Gibco Cat. A11138-03).
Cell proliferation assay
Cells were seeded in a 24 well plate (10,000 cells per well), and treated as indicated. The real time cell history recorder JULI TM Stage was used to record cell confluence every 6 hrs. Results are presented as the averaged confluence ±SEM. For the 4NQO-induced cell lines ( Figure 6 .B), cells were treated as indicated for 4 days and then fixed and stained with crystal violet. Results are presented as a percentage of the control (DMSO) treated cells.
Chromatin immunoprecipitation assay (ChIP)
ChIP experiments were performed using the Magna ChIP TM A (Merck, Catalog # 17-610), according to the manufacturer protocol. KYSE180 Sen or blue (HPV Pos ) symbol, and the size of the symbol correlates to the BYL719 IC:50 value of the cell line in M (i.e, the larger the symbol, the higher the IC:50. IC:50 values for HPV Neg cells were extracted from our previous report (14)). Figure 4: Silencing of c-JUN and c-FOS, or blocking c-JUN N- 
